Roberto Salvatori, MD
Professor of Medicine, Johns Hopkins University
Honors, Catholic University School of Medicine in Rome, Italy
Dr. Roberto Salvatori graduated summa cum laude with honors from Catholic University School of Medicine in Rome, Italy. He trained in Internal Medicine at the Montefiore Medical Center of the Albert Einstein University in the Bronx, NY and completed fellowships in Endocrinology and Metabolism at Cornell University in New York and at the Johns Hopkins University School of Medicine. He joined the Johns Hopkins faculty in 1998 and is currently a Professor of Medicine.
One of the founders of the Johns Hopkins Pituitary Tumor Center, Dr. Salvatori focuses his clinical practice on the diagnosis and treatment of pituitary and adrenal tumors and pituitary dysfunction, with a particular interest in growth hormone excess (acromegaly) and deficiency, and on cortisol excess (Cushing) and deficiency (adrenal insufficiency).
Dr. Salvatori is the director of the Johns Hopkins endocrinology fellowship training program.
Arun J. Sanyal, MD, FAASLD
Virginia Commonwealth University, Richmond, VA
Dr. Arun Sanyal is a Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine. He has over 25 years of experience as a hepatologist and has served as the secretary and president of the American Association for Study of Liver Diseases, a founding member of the Hepatology board of the American Board of Internal Medicine, Chair of the NIH hepatobiliary pathophysiology study section and Member of the council of the NIH. He has been continuously funded by the NIH for over 25 years.
Dr. Sanyal’s research spans the areas of cirrhosis and alcoholic- and nonalcoholic steatohepatitis (NASH). His work informs several recommendations in national practice guidelines related to the management of variceal hemorrhage, ascites, hepatorenal syndrome, hepatic encephalopathy, and NASH. He has helped establish and chair the “Liver Forum” which brings FDA, European Medical Agency, Academia, NIH and industry stakeholders in NASH and hepatic fibrosis together to accelerate therapeutic development in these areas.
Scott L Friedman, MD
Dean for Therapeutic Discovery and Professor of Medicine, Liver Diseases, Mt. Sinai
Dr. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at Mount Sinai. He has performed pioneering research into the underlying causes of scarring, or fibrosis associated with chronic liver disease. Dr. Friedman was among the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. His work has spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials. He is a widely respected author with over 300 peer-reviewed publications focused on the research and treatment of liver disease.
He served as Chief of the Division of Liver Diseases at Mount Sinai since 2001 and in 2012 as Dean for Therapeutic. As President of the American Assn. for the Study of Liver Diseases in 2009, Dr. Friedman oversaw several major new initiatives that accelerated its growth and brought the Association to new levels of income and international visibility.